Review



prb s780  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc prb s780
    Changes in Ki-67 and phosphorylated Rb in tumor tissue and skin. (A) Analysis of pharmacodynamic markers show marked reduction in on-treatment biopsy. Representative tumor biopsy specimens (patient 214-0143) obtained pre-treatment and on-treatment (C1D17) were stained using antibodies to phospho-retinoblastoma protein [pRb <t>(S780)],</t> total Rb, and Ki-67. (B) The box plot depicts the expression of Ki-67, total-Rb, and pRb in 27 paired tumor tissue samples, as determined by percentage of cells staining positive. Data are presented before and after treatment, regardless of palbociclib dose level or endocrine therapy partner. (C) The box plot depicts the change in the percent of cells staining positive for expression of Ki-67, total Rb, and pRb in tumor tissue samples between baseline and on-treatment for patients receiving both 100 mg and 125 mg of palbociclib. (D) The box plot depicts pRb and Ki-67 expression, as determined by the percentage of cells staining positive in 66 paired skin biopsies taken at baseline and between day 14 and 21 of the first cycle of palbociclib. Expression is shown pre-treatment and on-treatment at both dose levels of palbociclib. pRb, phosphorylated retinoblastoma protein; total-Rb, total retinoblastoma protein; Pre, pre-treatment; On-Tx, on-treatment
    Prb S780, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prb+s780/pmc12995829-102-18-20?v=Cell+Signaling+Technology+Inc
    Average 86 stars, based on 1 article reviews
    prb s780 - by Bioz Stars, 2026-07
    86/100 stars

    Images

    1) Product Images from "TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer"

    Article Title: TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer

    Journal: ESMO Open

    doi: 10.1016/j.esmoop.2026.106063

    Changes in Ki-67 and phosphorylated Rb in tumor tissue and skin. (A) Analysis of pharmacodynamic markers show marked reduction in on-treatment biopsy. Representative tumor biopsy specimens (patient 214-0143) obtained pre-treatment and on-treatment (C1D17) were stained using antibodies to phospho-retinoblastoma protein [pRb (S780)], total Rb, and Ki-67. (B) The box plot depicts the expression of Ki-67, total-Rb, and pRb in 27 paired tumor tissue samples, as determined by percentage of cells staining positive. Data are presented before and after treatment, regardless of palbociclib dose level or endocrine therapy partner. (C) The box plot depicts the change in the percent of cells staining positive for expression of Ki-67, total Rb, and pRb in tumor tissue samples between baseline and on-treatment for patients receiving both 100 mg and 125 mg of palbociclib. (D) The box plot depicts pRb and Ki-67 expression, as determined by the percentage of cells staining positive in 66 paired skin biopsies taken at baseline and between day 14 and 21 of the first cycle of palbociclib. Expression is shown pre-treatment and on-treatment at both dose levels of palbociclib. pRb, phosphorylated retinoblastoma protein; total-Rb, total retinoblastoma protein; Pre, pre-treatment; On-Tx, on-treatment
    Figure Legend Snippet: Changes in Ki-67 and phosphorylated Rb in tumor tissue and skin. (A) Analysis of pharmacodynamic markers show marked reduction in on-treatment biopsy. Representative tumor biopsy specimens (patient 214-0143) obtained pre-treatment and on-treatment (C1D17) were stained using antibodies to phospho-retinoblastoma protein [pRb (S780)], total Rb, and Ki-67. (B) The box plot depicts the expression of Ki-67, total-Rb, and pRb in 27 paired tumor tissue samples, as determined by percentage of cells staining positive. Data are presented before and after treatment, regardless of palbociclib dose level or endocrine therapy partner. (C) The box plot depicts the change in the percent of cells staining positive for expression of Ki-67, total Rb, and pRb in tumor tissue samples between baseline and on-treatment for patients receiving both 100 mg and 125 mg of palbociclib. (D) The box plot depicts pRb and Ki-67 expression, as determined by the percentage of cells staining positive in 66 paired skin biopsies taken at baseline and between day 14 and 21 of the first cycle of palbociclib. Expression is shown pre-treatment and on-treatment at both dose levels of palbociclib. pRb, phosphorylated retinoblastoma protein; total-Rb, total retinoblastoma protein; Pre, pre-treatment; On-Tx, on-treatment

    Techniques Used: Staining, Expressing



    Similar Products

    prb s780  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc prb s780
    Changes in Ki-67 and phosphorylated Rb in tumor tissue and skin. (A) Analysis of pharmacodynamic markers show marked reduction in on-treatment biopsy. Representative tumor biopsy specimens (patient 214-0143) obtained pre-treatment and on-treatment (C1D17) were stained using antibodies to phospho-retinoblastoma protein [pRb <t>(S780)],</t> total Rb, and Ki-67. (B) The box plot depicts the expression of Ki-67, total-Rb, and pRb in 27 paired tumor tissue samples, as determined by percentage of cells staining positive. Data are presented before and after treatment, regardless of palbociclib dose level or endocrine therapy partner. (C) The box plot depicts the change in the percent of cells staining positive for expression of Ki-67, total Rb, and pRb in tumor tissue samples between baseline and on-treatment for patients receiving both 100 mg and 125 mg of palbociclib. (D) The box plot depicts pRb and Ki-67 expression, as determined by the percentage of cells staining positive in 66 paired skin biopsies taken at baseline and between day 14 and 21 of the first cycle of palbociclib. Expression is shown pre-treatment and on-treatment at both dose levels of palbociclib. pRb, phosphorylated retinoblastoma protein; total-Rb, total retinoblastoma protein; Pre, pre-treatment; On-Tx, on-treatment
    Prb S780, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prb+s780/pmc12995829-102-18-20?v=Cell+Signaling+Technology+Inc
    Average 86 stars, based on 1 article reviews
    prb s780 - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    none prb s780 rabbit cell signalling  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc none prb s780 rabbit cell signalling
    Changes in Ki-67 and phosphorylated Rb in tumor tissue and skin. (A) Analysis of pharmacodynamic markers show marked reduction in on-treatment biopsy. Representative tumor biopsy specimens (patient 214-0143) obtained pre-treatment and on-treatment (C1D17) were stained using antibodies to phospho-retinoblastoma protein [pRb <t>(S780)],</t> total Rb, and Ki-67. (B) The box plot depicts the expression of Ki-67, total-Rb, and pRb in 27 paired tumor tissue samples, as determined by percentage of cells staining positive. Data are presented before and after treatment, regardless of palbociclib dose level or endocrine therapy partner. (C) The box plot depicts the change in the percent of cells staining positive for expression of Ki-67, total Rb, and pRb in tumor tissue samples between baseline and on-treatment for patients receiving both 100 mg and 125 mg of palbociclib. (D) The box plot depicts pRb and Ki-67 expression, as determined by the percentage of cells staining positive in 66 paired skin biopsies taken at baseline and between day 14 and 21 of the first cycle of palbociclib. Expression is shown pre-treatment and on-treatment at both dose levels of palbociclib. pRb, phosphorylated retinoblastoma protein; total-Rb, total retinoblastoma protein; Pre, pre-treatment; On-Tx, on-treatment
    None Prb S780 Rabbit Cell Signalling, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prb+s780/pmc03852888__pone__0082076__s006-0-68-72?v=Cell+Signaling+Technology+Inc
    Average 96 stars, based on 1 article reviews
    none prb s780 rabbit cell signalling - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    anti prb s780  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc anti prb s780
    Changes in Ki-67 and phosphorylated Rb in tumor tissue and skin. (A) Analysis of pharmacodynamic markers show marked reduction in on-treatment biopsy. Representative tumor biopsy specimens (patient 214-0143) obtained pre-treatment and on-treatment (C1D17) were stained using antibodies to phospho-retinoblastoma protein [pRb <t>(S780)],</t> total Rb, and Ki-67. (B) The box plot depicts the expression of Ki-67, total-Rb, and pRb in 27 paired tumor tissue samples, as determined by percentage of cells staining positive. Data are presented before and after treatment, regardless of palbociclib dose level or endocrine therapy partner. (C) The box plot depicts the change in the percent of cells staining positive for expression of Ki-67, total Rb, and pRb in tumor tissue samples between baseline and on-treatment for patients receiving both 100 mg and 125 mg of palbociclib. (D) The box plot depicts pRb and Ki-67 expression, as determined by the percentage of cells staining positive in 66 paired skin biopsies taken at baseline and between day 14 and 21 of the first cycle of palbociclib. Expression is shown pre-treatment and on-treatment at both dose levels of palbociclib. pRb, phosphorylated retinoblastoma protein; total-Rb, total retinoblastoma protein; Pre, pre-treatment; On-Tx, on-treatment
    Anti Prb S780, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prb+s780/pm40287441-210-99-102?v=Cell+Signaling+Technology+Inc
    Average 96 stars, based on 1 article reviews
    anti prb s780 - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Changes in Ki-67 and phosphorylated Rb in tumor tissue and skin. (A) Analysis of pharmacodynamic markers show marked reduction in on-treatment biopsy. Representative tumor biopsy specimens (patient 214-0143) obtained pre-treatment and on-treatment (C1D17) were stained using antibodies to phospho-retinoblastoma protein [pRb (S780)], total Rb, and Ki-67. (B) The box plot depicts the expression of Ki-67, total-Rb, and pRb in 27 paired tumor tissue samples, as determined by percentage of cells staining positive. Data are presented before and after treatment, regardless of palbociclib dose level or endocrine therapy partner. (C) The box plot depicts the change in the percent of cells staining positive for expression of Ki-67, total Rb, and pRb in tumor tissue samples between baseline and on-treatment for patients receiving both 100 mg and 125 mg of palbociclib. (D) The box plot depicts pRb and Ki-67 expression, as determined by the percentage of cells staining positive in 66 paired skin biopsies taken at baseline and between day 14 and 21 of the first cycle of palbociclib. Expression is shown pre-treatment and on-treatment at both dose levels of palbociclib. pRb, phosphorylated retinoblastoma protein; total-Rb, total retinoblastoma protein; Pre, pre-treatment; On-Tx, on-treatment

    Journal: ESMO Open

    Article Title: TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer

    doi: 10.1016/j.esmoop.2026.106063

    Figure Lengend Snippet: Changes in Ki-67 and phosphorylated Rb in tumor tissue and skin. (A) Analysis of pharmacodynamic markers show marked reduction in on-treatment biopsy. Representative tumor biopsy specimens (patient 214-0143) obtained pre-treatment and on-treatment (C1D17) were stained using antibodies to phospho-retinoblastoma protein [pRb (S780)], total Rb, and Ki-67. (B) The box plot depicts the expression of Ki-67, total-Rb, and pRb in 27 paired tumor tissue samples, as determined by percentage of cells staining positive. Data are presented before and after treatment, regardless of palbociclib dose level or endocrine therapy partner. (C) The box plot depicts the change in the percent of cells staining positive for expression of Ki-67, total Rb, and pRb in tumor tissue samples between baseline and on-treatment for patients receiving both 100 mg and 125 mg of palbociclib. (D) The box plot depicts pRb and Ki-67 expression, as determined by the percentage of cells staining positive in 66 paired skin biopsies taken at baseline and between day 14 and 21 of the first cycle of palbociclib. Expression is shown pre-treatment and on-treatment at both dose levels of palbociclib. pRb, phosphorylated retinoblastoma protein; total-Rb, total retinoblastoma protein; Pre, pre-treatment; On-Tx, on-treatment

    Article Snippet: Baseline and on-treatment skin punch and tumor core biopsies were formalin-fixed, paraffin-embedded, sectioned (5 μM), and stained for pRb (S780) (Cell Signaling Technology #9308, Danvers, MA), total Rb (clone 3C8, LS-3414, Abnova, Taipei City, Taiwan), and Ki-67 (clone MIB-1, #M7240, Agilent Dako, Santa Clara, CA) on the Leica BOND IHC platform using 3, 3-diaminobenzidine or polymer red detection (to reduce melanin background).

    Techniques: Staining, Expressing